Practice Test Geeks(MTM) Medication Therapy Management Certification for Pharmacists Practice Test
← All MTM Flashcard Decks

Diabetes & Cardiovascular Pharmacotherapy Flashcards

7 cards from real MTM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Diabetes & Cardiovascular Pharmacotherapy flashcards as text

  1. A patient with T2DM and heart failure with reduced ejection fraction (HFrEF) is on an SGLT2 inhibitor. Which additional medication class has been shown to reduce mortality in HFrEF?

    Answer: Sacubitril/valsartan (ARNI)

    Sacubitril/valsartan is a guideline-directed therapy for HFrEF that reduces mortality and is appropriate alongside SGLT2 inhibitors.

  2. Which DPP-4 inhibitor has been shown to increase the risk of hospitalization for heart failure in the SAVOR-TIMI trial?

    Answer: Saxagliptin

    Saxagliptin (SAVOR-TIMI 53) was associated with a statistically significant increase in hospitalization for heart failure.

  3. A patient on warfarin for atrial fibrillation starts insulin glargine for newly diagnosed T2DM. What counseling point is most important?

    Answer: Hypoglycemia can alter INR monitoring accuracy

    Significant hypoglycemia can affect INR readings and alter hepatic metabolism, requiring closer anticoagulation monitoring.

  4. Which of the following statins carries the highest risk of myopathy due to drug interactions with CYP3A4 inhibitors?

    Answer: Simvastatin

    Simvastatin is extensively metabolized by CYP3A4, making it most susceptible to dose-dependent myopathy when combined with strong CYP3A4 inhibitors.

  5. A diabetic patient with prior MI and LDL of 85 mg/dL on high-intensity statin therapy asks if they need additional lipid-lowering therapy. According to ACC/AHA guidelines, what is the LDL target for very high-risk ASCVD patients?

    Answer: Less than 70 mg/dL

    ACC/AHA guidelines recommend an LDL goal of less than 70 mg/dL for very high-risk ASCVD patients, with ezetimibe or PCSK9 inhibitors added if needed.

  6. Which beta-blocker is considered cardioselective and preferred in patients with T2DM and hypertension?

    Answer: Metoprolol succinate

    Metoprolol succinate is a cardioselective beta-1 blocker that has less tendency to mask hypoglycemic symptoms and blunt counter-regulatory responses than non-selective agents.

  7. A patient with T2DM and peripheral artery disease (PAD) is initiated on antiplatelet therapy. Which agent is preferred over aspirin alone based on COMPASS trial data?

    Answer: Aspirin plus low-dose rivaroxaban

    The COMPASS trial showed that aspirin plus low-dose rivaroxaban (2.5 mg BID) significantly reduced major adverse limb and CV events in patients with PAD.